7 September 2022 - Tarsus Pharmaceuticals today announced that it has submitted a new drug application to the US FDA for TP-03 (lotilaner 0.25% ophthalmic solution) for the treatment of Demodex blepharitis.

The new drug application submission includes the positive results from the two pivotal trials (Saturn-1 and Saturn-2) collectively involving more than 800 patients in which TP-03 met all endpoints and was well-tolerated.

Read Tarsus Pharmaceuticals press release